ID   HDAC4_HUMAN             Reviewed;        1084 AA.
AC   P56524; E9PGB9; F5GX36; Q86YH7; Q9UND6;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 3.
DT   28-JAN-2026, entry version 236.
DE   RecName: Full=Histone deacetylase 4 {ECO:0000305|PubMed:10220385};
DE            Short=HD4;
DE            EC=3.5.1.98 {ECO:0000269|PubMed:10220385, ECO:0000269|PubMed:10523670, ECO:0000269|PubMed:12032081};
GN   Name=HDAC4 {ECO:0000312|HGNC:HGNC:14063}; Synonyms=KIAA0288;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY.
RC   TISSUE=Leukemia;
RX   PubMed=10220385; DOI=10.1073/pnas.96.9.4868;
RA   Grozinger C.M., Hassig C.A., Schreiber S.L.;
RT   "Three proteins define a class of human histone deacetylases related to
RT   yeast Hda1p.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4868-4873(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9179496; DOI=10.1093/dnares/4.1.53;
RA   Ohara O., Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N.,
RA   Nomura N.;
RT   "Construction and characterization of human brain cDNA libraries suitable
RT   for analysis of cDNA clones encoding relatively large proteins.";
RL   DNA Res. 4:53-59(1997).
RN   [3]
RP   SEQUENCE REVISION TO N-TERMINUS.
RA   Ohara O., Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N.,
RA   Nomura N.;
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH MEF2A.
RX   PubMed=10487761; DOI=10.1093/emboj/18.18.5099;
RA   Miska E.A., Karlsson C., Langley E., Nielsen S.J., Pines J., Kouzarides T.;
RT   "HDAC4 deacetylase associates with and represses the MEF2 transcription
RT   factor.";
RL   EMBO J. 18:5099-5107(1999).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH MEF2C AND MEF2D, AND
RP   MUTAGENESIS OF HIS-803.
RX   PubMed=10523670; DOI=10.1128/mcb.19.11.7816;
RA   Wang A.H., Bertos N.R., Vezmar M., Pelletier N., Crosato M., Heng H.H.,
RA   Th'ng J., Han J., Yang X.-J.;
RT   "HDAC4, a human histone deacetylase related to yeast HDA1, is a
RT   transcriptional corepressor.";
RL   Mol. Cell. Biol. 19:7816-7827(1999).
RN   [9]
RP   PHOSPHORYLATION AT SER-246; SER-467 AND SER-632, MUTAGENESIS OF SER-246;
RP   SER-467 AND SER-632, AND INTERACTION WITH 14-3-3 PROTEINS.
RX   PubMed=10958686; DOI=10.1128/mcb.20.18.6904-6912.2000;
RA   Wang A.H., Kruhlak M.J., Wu J., Bertos N.R., Vezmar M., Posner B.I.,
RA   Bazett-Jones D.P., Yang X.-J.;
RT   "Regulation of histone deacetylase 4 by binding of 14-3-3 proteins.";
RL   Mol. Cell. Biol. 20:6904-6912(2000).
RN   [10]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND MUTAGENESIS OF SER-467 AND
RP   SER-632.
RX   PubMed=11470791; DOI=10.1074/jbc.m105086200;
RA   Zhao X., Ito A., Kane C.D., Liao T.-S., Bolger T.A., Lemrow S.M.,
RA   Means A.R., Yao T.-P.;
RT   "The modular nature of histone deacetylase HDAC4 confers phosphorylation-
RT   dependent intracellular trafficking.";
RL   J. Biol. Chem. 276:35042-35048(2001).
RN   [11]
RP   NUCLEAR EXPORT SIGNAL, AND MUTAGENESIS OF VAL-1056 AND LEU-1062.
RX   PubMed=11509672; DOI=10.1128/mcb.21.18.6312-6321.2001;
RA   McKinsey T.A., Zhang C.-L., Olson E.N.;
RT   "Identification of a signal-responsive nuclear export sequence in class II
RT   histone deacetylases.";
RL   Mol. Cell. Biol. 21:6312-6321(2001).
RN   [12]
RP   INTERACTION WITH NR2C1.
RX   PubMed=11463856; DOI=10.1210/mend.15.8.0682;
RA   Franco P.J., Farooqui M., Seto E., Wei L.-N.;
RT   "The orphan nuclear receptor TR2 interacts directly with both class I and
RT   class II histone deacetylases.";
RL   Mol. Endocrinol. 15:1318-1328(2001).
RN   [13]
RP   CATALYTIC ACTIVITY, HOMODIMERIZATION, SUMOYLATION AT LYS-559, AND
RP   MUTAGENESIS OF LYS-559.
RX   PubMed=12032081; DOI=10.1093/emboj/21.11.2682;
RA   Kirsh O., Seeler J.-S., Pichler A., Gast A., Mueller S., Miska E.,
RA   Mathieu M., Harel-Bellan A., Kouzarides T., Melchior F., Dejean A.;
RT   "The SUMO E3 ligase RanBP2 promotes modification of the HDAC4
RT   deacetylase.";
RL   EMBO J. 21:2682-2691(2002).
RN   [14]
RP   INTERACTION WITH KDM5B.
RX   PubMed=17373667; DOI=10.1002/ijc.22673;
RA   Barrett A., Santangelo S., Tan K., Catchpole S., Roberts K.,
RA   Spencer-Dene B., Hall D., Scibetta A., Burchell J., Verdin E., Freemont P.,
RA   Taylor-Papadimitriou J.;
RT   "Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts
RT   directly with histone deacetylases.";
RL   Int. J. Cancer 121:265-275(2007).
RN   [15]
RP   PHOSPHORYLATION BY CAMK2D.
RX   PubMed=17179159; DOI=10.1074/jbc.m604281200;
RA   Little G.H., Bai Y., Williams T., Poizat C.;
RT   "Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially
RT   transmits signals to histone deacetylase 4 in cardiac cells.";
RL   J. Biol. Chem. 282:7219-7231(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-632 AND SER-633, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-350, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   INVOLVEMENT IN BDMR.
RX   PubMed=20691407; DOI=10.1016/j.ajhg.2010.07.011;
RA   Williams S.R., Aldred M.A., Der Kaloustian V.M., Halal F., Gowans G.,
RA   McLeod D.R., Zondag S., Toriello H.V., Magenis R.E., Elsea S.H.;
RT   "Haploinsufficiency of HDAC4 causes brachydactyly mental retardation
RT   syndrome, with brachydactyly type E, developmental delays, and behavioral
RT   problems.";
RL   Am. J. Hum. Genet. 87:219-228(2010).
RN   [19]
RP   INTERACTION WITH MORC2.
RX   PubMed=20110259; DOI=10.1093/nar/gkq006;
RA   Shao Y., Li Y., Zhang J., Liu D., Liu F., Zhao Y., Shen T., Li F.;
RT   "Involvement of histone deacetylation in MORC2-mediated down-regulation of
RT   carbonic anhydrase IX.";
RL   Nucleic Acids Res. 38:2813-2824(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   INVOLVEMENT IN BDMR.
RX   PubMed=23188045; DOI=10.1038/ejhg.2012.240;
RA   Villavicencio-Lorini P., Klopocki E., Trimborn M., Koll R., Mundlos S.,
RA   Horn D.;
RT   "Phenotypic variant of Brachydactyly-mental retardation syndrome in a
RT   family with an inherited interstitial 2q37.3 microdeletion including
RT   HDAC4.";
RL   Eur. J. Hum. Genet. 21:743-748(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-632, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH EP300.
RX   PubMed=24413532; DOI=10.1158/0008-5472.can-13-2020;
RA   Kang H.J., Lee M.H., Kang H.L., Kim S.H., Ahn J.R., Na H., Na T.Y.,
RA   Kim Y.N., Seong J.K., Lee M.O.;
RT   "Differential regulation of estrogen receptor alpha expression in breast
RT   cancer cells by metastasis-associated protein 1.";
RL   Cancer Res. 74:1484-1494(2014).
RN   [25]
RP   INVOLVEMENT IN BDMR.
RX   PubMed=24715439; DOI=10.1002/ajmg.a.36542;
RA   Wheeler P.G., Huang D., Dai Z.;
RT   "Haploinsufficiency of HDAC4 does not cause intellectual disability in all
RT   affected individuals.";
RL   Am. J. Med. Genet. A 164A:1826-1829(2014).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-632, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   INTERACTION WITH CUL7 AND ANKRA2, AND MUTAGENESIS OF PRO-349 AND ILE-354.
RX   PubMed=25752541; DOI=10.1016/j.str.2015.02.001;
RA   Nie J., Xu C., Jin J., Aka J.A., Tempel W., Nguyen V., You L., Weist R.,
RA   Min J., Pawson T., Yang X.J.;
RT   "Ankyrin repeats of ANKRA2 recognize a PxLPxL motif on the 3M syndrome
RT   protein CCDC8.";
RL   Structure 23:700-712(2015).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH HSPA1A AND HSPA1B.
RX   PubMed=27708256; DOI=10.1038/ncomms12882;
RA   Seo J.H., Park J.H., Lee E.J., Vo T.T., Choi H., Kim J.Y., Jang J.K.,
RA   Wee H.J., Lee H.S., Jang S.H., Park Z.Y., Jeong J., Lee K.J., Seok S.H.,
RA   Park J.Y., Lee B.J., Lee M.N., Oh G.T., Kim K.W.;
RT   "ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding
RT   and degradation.";
RL   Nat. Commun. 7:12882-12882(2016).
RN   [29]
RP   INTERACTION WITH ZNF638.
RX   PubMed=30487602; DOI=10.1038/s41586-018-0750-6;
RA   Zhu Y., Wang G.Z., Cingoez O., Goff S.P.;
RT   "NP220 mediates silencing of unintegrated retroviral DNA.";
RL   Nature 564:278-282(2018).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 343-359 IN COMPLEX WITH ANKRA2,
RP   PHOSPHORYLATION AT SER-350, MOTIF, AND MUTAGENESIS OF LEU-345; TYR-346;
RP   THR-347; SER-348; PRO-349; SER-350; LEU-351; PRO-352; ASN-353; ILE-354;
RP   THR-355 AND LEU-356.
RX   PubMed=22649097; DOI=10.1126/scisignal.2002979;
RA   Xu C., Jin J., Bian C., Lam R., Tian R., Weist R., You L., Nie J.,
RA   Bochkarev A., Tempel W., Tan C.S., Wasney G.A., Vedadi M., Gish G.D.,
RA   Arrowsmith C.H., Pawson T., Yang X.J., Min J.;
RT   "Sequence-specific recognition of a PxLPxI/L motif by an ankyrin repeat
RT   tumbler lock.";
RL   Sci. Signal. 5:RA39-RA39(2012).
RN   [31]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-727.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [32]
RP   VARIANT ILE-754.
RX   PubMed=24169519; DOI=10.1038/ejhg.2013.243;
RA   Piton A., Poquet H., Redin C., Masurel A., Lauer J., Muller J.,
RA   Thevenon J., Herenger Y., Chancenotte S., Bonnet M., Pinoit J.M., Huet F.,
RA   Thauvin-Robinet C., Jaeger A.S., Le Gras S., Jost B., Gerard B., Peoc'h K.,
RA   Launay J.M., Faivre L., Mandel J.L.;
RT   "20 ans apres: a second mutation in MAOA identified by targeted high-
RT   throughput sequencing in a family with altered behavior and cognition.";
RL   Eur. J. Hum. Genet. 22:776-783(2014).
RN   [33]
RP   VARIANTS NEDCHF LYS-244; GLY-247; ALA-248 AND LEU-248, INVOLVEMENT IN
RP   NEDCHF, CHARACTERIZATION OF VARIANTS NEDCHF LYS-244 AND GLY-247, AND
RP   INTERACTION WITH YWHAB.
RX   PubMed=33537682; DOI=10.1016/j.xhgg.2020.100015;
RG   DDD Study;
RA   Wakeling E., McEntagart M., Bruccoleri M., Shaw-Smith C., Stals K.L.,
RA   Wakeling M., Barnicoat A., Beesley C., Hanson-Kahn A.K., Kukolich M.,
RA   Stevenson D.A., Campeau P.M., Ellard S., Elsea S.H., Yang X.J.,
RA   Caswell R.C.;
RT   "Missense substitutions at a conserved 14-3-3 binding site in HDAC4 cause a
RT   novel intellectual disability syndrome.";
RL   HGG Adv. 2:100015-100015(2021).
CC   -!- FUNCTION: Responsible for the deacetylation of lysine residues on the
CC       N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone
CC       deacetylation gives a tag for epigenetic repression and plays an
CC       important role in transcriptional regulation, cell cycle progression
CC       and developmental events. Histone deacetylases act via the formation of
CC       large multiprotein complexes. Involved in muscle maturation via its
CC       interaction with the myocyte enhancer factors such as MEF2A, MEF2C and
CC       MEF2D. Involved in the MTA1-mediated epigenetic regulation of ESR1
CC       expression in breast cancer. Deacetylates HSPA1A and HSPA1B at 'Lys-77'
CC       leading to their preferential binding to co-chaperone STUB1
CC       (PubMed:27708256). {ECO:0000269|PubMed:10523670,
CC       ECO:0000269|PubMed:24413532, ECO:0000269|PubMed:27708256}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-acetyl-L-lysyl-[histone] + H2O = L-lysyl-[histone] +
CC         acetate; Xref=Rhea:RHEA:58196, Rhea:RHEA-COMP:9845, Rhea:RHEA-
CC         COMP:11338, ChEBI:CHEBI:15377, ChEBI:CHEBI:29969, ChEBI:CHEBI:30089,
CC         ChEBI:CHEBI:61930; EC=3.5.1.98;
CC         Evidence={ECO:0000269|PubMed:10220385, ECO:0000269|PubMed:10523670,
CC         ECO:0000269|PubMed:12032081};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:58197;
CC         Evidence={ECO:0000269|PubMed:10523670, ECO:0000269|PubMed:12032081};
CC   -!- SUBUNIT: Homodimer. Homodimerization via its N-terminal domain
CC       (PubMed:12032081). Interacts with MEF2A (PubMed:10487761). Interacts
CC       with MEF2C and MEF2D (PubMed:10523670). Interacts with AHRR (By
CC       similarity). Interacts with NR2C1 (PubMed:11463856). Interacts with
CC       HDAC7 (By similarity). Interacts with a 14-3-3 chaperone proteins in a
CC       phosphorylation dependent manner (PubMed:10958686). Interacts with 14-
CC       3-3 protein YWHAB (PubMed:33537682). Interacts with BTBD14B (By
CC       similarity). Interacts with KDM5B (PubMed:17373667). Interacts with
CC       MYOCD (By similarity). Interacts with MORC2 (PubMed:20110259).
CC       Interacts (via PxLPxI/L motif) with ANKRA2 (via ankyrin repeats).
CC       Interacts with CUL7 (as part of the 3M complex); negatively regulated
CC       by ANKRA2 (PubMed:25752541). Interacts with EP300 in the presence of
CC       TFAP2C (PubMed:24413532). Interacts with HSPA1A and HSPA1B leading to
CC       their deacetylation at 'Lys-77' (PubMed:27708256). Interacts with
CC       ZBTB7B; the interaction allows the recruitment of HDAC4 on CD8 loci for
CC       deacetylation and possible inhibition of CD8 genes expression (By
CC       similarity). Interacts with DHX36 (By similarity). Interacts with SIK3;
CC       this interaction leads to HDAC4 retention in the cytoplasm (By
CC       similarity). Interacts with ZNF638 (PubMed:30487602).
CC       {ECO:0000250|UniProtKB:Q6NZM9, ECO:0000250|UniProtKB:Q99P99,
CC       ECO:0000269|PubMed:10487761, ECO:0000269|PubMed:10523670,
CC       ECO:0000269|PubMed:10958686, ECO:0000269|PubMed:11463856,
CC       ECO:0000269|PubMed:17373667, ECO:0000269|PubMed:20110259,
CC       ECO:0000269|PubMed:22649097, ECO:0000269|PubMed:24413532,
CC       ECO:0000269|PubMed:25752541, ECO:0000269|PubMed:27708256,
CC       ECO:0000269|PubMed:30487602, ECO:0000269|PubMed:33537682}.
CC   -!- INTERACTION:
CC       P56524; Q9H9E1: ANKRA2; NbExp=3; IntAct=EBI-308629, EBI-10215533;
CC       P56524; P10275: AR; NbExp=4; IntAct=EBI-308629, EBI-608057;
CC       P56524; P15336: ATF2; NbExp=2; IntAct=EBI-308629, EBI-1170906;
CC       P56524; P41182: BCL6; NbExp=3; IntAct=EBI-308629, EBI-765407;
CC       P56524; Q9HCU9: BRMS1; NbExp=2; IntAct=EBI-308629, EBI-714781;
CC       P56524; Q96JN2-2: CCDC136; NbExp=3; IntAct=EBI-308629, EBI-10171416;
CC       P56524; Q01850: CDR2; NbExp=3; IntAct=EBI-308629, EBI-1181367;
CC       P56524; O95967: EFEMP2; NbExp=3; IntAct=EBI-308629, EBI-743414;
CC       P56524; Q08379: GOLGA2; NbExp=3; IntAct=EBI-308629, EBI-618309;
CC       P56524; P56524: HDAC4; NbExp=4; IntAct=EBI-308629, EBI-308629;
CC       P56524; Q15323: KRT31; NbExp=3; IntAct=EBI-308629, EBI-948001;
CC       P56524; O76015: KRT38; NbExp=3; IntAct=EBI-308629, EBI-1047263;
CC       P56524; Q6A162: KRT40; NbExp=3; IntAct=EBI-308629, EBI-10171697;
CC       P56524; O95751: LDOC1; NbExp=3; IntAct=EBI-308629, EBI-740738;
CC       P56524; A9UHW6: MIF4GD; NbExp=4; IntAct=EBI-308629, EBI-373498;
CC       P56524; Q5JR59: MTUS2; NbExp=3; IntAct=EBI-308629, EBI-742948;
CC       P56524; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-308629, EBI-302345;
CC       P56524; Q6NUQ1: RINT1; NbExp=3; IntAct=EBI-308629, EBI-726876;
CC       P56524; Q13761: RUNX3; NbExp=9; IntAct=EBI-308629, EBI-925990;
CC       P56524; P31947: SFN; NbExp=8; IntAct=EBI-308629, EBI-476295;
CC       P56524; P63279: UBE2I; NbExp=3; IntAct=EBI-308629, EBI-80168;
CC       P56524; P31946: YWHAB; NbExp=7; IntAct=EBI-308629, EBI-359815;
CC       P56524; P62258: YWHAE; NbExp=9; IntAct=EBI-308629, EBI-356498;
CC       P56524; P61981: YWHAG; NbExp=15; IntAct=EBI-308629, EBI-359832;
CC       P56524; Q04917: YWHAH; NbExp=10; IntAct=EBI-308629, EBI-306940;
CC       P56524; P27348: YWHAQ; NbExp=7; IntAct=EBI-308629, EBI-359854;
CC       P56524; P63104: YWHAZ; NbExp=9; IntAct=EBI-308629, EBI-347088;
CC       P56524; O54946-2: Dnajb6; Xeno; NbExp=2; IntAct=EBI-308629, EBI-13941040;
CC       P56524; Q8AZK7: EBNA-LP; Xeno; NbExp=5; IntAct=EBI-308629, EBI-1185167;
CC       P56524; P08393: ICP0; Xeno; NbExp=3; IntAct=EBI-308629, EBI-6148881;
CC       P56524-2; Q8WXK1: ASB15; NbExp=3; IntAct=EBI-11953488, EBI-12809012;
CC       P56524-2; Q9BUH8: BEGAIN; NbExp=3; IntAct=EBI-11953488, EBI-742722;
CC       P56524-2; Q8TD16-2: BICD2; NbExp=3; IntAct=EBI-11953488, EBI-11975051;
CC       P56524-2; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-11953488, EBI-2548012;
CC       P56524-2; A2RRN7: CADPS; NbExp=3; IntAct=EBI-11953488, EBI-10179719;
CC       P56524-2; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-11953488, EBI-739580;
CC       P56524-2; Q86Z20: CCDC125; NbExp=3; IntAct=EBI-11953488, EBI-11977221;
CC       P56524-2; O95273: CCNDBP1; NbExp=3; IntAct=EBI-11953488, EBI-748961;
CC       P56524-2; Q6NVV7: CDPF1; NbExp=3; IntAct=EBI-11953488, EBI-2802782;
CC       P56524-2; Q01850: CDR2; NbExp=3; IntAct=EBI-11953488, EBI-1181367;
CC       P56524-2; Q86X02: CDR2L; NbExp=3; IntAct=EBI-11953488, EBI-11063830;
CC       P56524-2; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-11953488, EBI-739624;
CC       P56524-2; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-11953488, EBI-740680;
CC       P56524-2; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-11953488, EBI-2349927;
CC       P56524-2; O94868-3: FCHSD2; NbExp=3; IntAct=EBI-11953488, EBI-11958845;
CC       P56524-2; A1L4K1: FSD2; NbExp=3; IntAct=EBI-11953488, EBI-5661036;
CC       P56524-2; Q08379: GOLGA2; NbExp=3; IntAct=EBI-11953488, EBI-618309;
CC       P56524-2; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-11953488, EBI-5916454;
CC       P56524-2; Q4V328: GRIPAP1; NbExp=3; IntAct=EBI-11953488, EBI-717919;
CC       P56524-2; P54257: HAP1; NbExp=3; IntAct=EBI-11953488, EBI-712814;
CC       P56524-2; Q96ED9-2: HOOK2; NbExp=3; IntAct=EBI-11953488, EBI-10961706;
CC       P56524-2; O75031: HSF2BP; NbExp=3; IntAct=EBI-11953488, EBI-7116203;
CC       P56524-2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-11953488, EBI-6509505;
CC       P56524-2; Q7Z3Y8: KRT27; NbExp=3; IntAct=EBI-11953488, EBI-3044087;
CC       P56524-2; Q15323: KRT31; NbExp=3; IntAct=EBI-11953488, EBI-948001;
CC       P56524-2; Q14525: KRT33B; NbExp=3; IntAct=EBI-11953488, EBI-1049638;
CC       P56524-2; O76011: KRT34; NbExp=3; IntAct=EBI-11953488, EBI-1047093;
CC       P56524-2; Q92764: KRT35; NbExp=3; IntAct=EBI-11953488, EBI-1058674;
CC       P56524-2; Q6A162: KRT40; NbExp=3; IntAct=EBI-11953488, EBI-10171697;
CC       P56524-2; O95751: LDOC1; NbExp=3; IntAct=EBI-11953488, EBI-740738;
CC       P56524-2; Q02078-5: MEF2A; NbExp=3; IntAct=EBI-11953488, EBI-12232917;
CC       P56524-2; Q02080: MEF2B; NbExp=3; IntAct=EBI-11953488, EBI-6427785;
CC       P56524-2; Q06413: MEF2C; NbExp=5; IntAct=EBI-11953488, EBI-2684075;
CC       P56524-2; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-11953488, EBI-10172526;
CC       P56524-2; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-11953488, EBI-11522433;
CC       P56524-2; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-11953488, EBI-10271199;
CC       P56524-2; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-11953488, EBI-79165;
CC       P56524-2; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-11953488, EBI-2212028;
CC       P56524-2; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-11953488, EBI-1105213;
CC       P56524-2; Q08117-2: TLE5; NbExp=3; IntAct=EBI-11953488, EBI-11741437;
CC       P56524-2; Q96RU7: TRIB3; NbExp=3; IntAct=EBI-11953488, EBI-492476;
CC       P56524-2; P14373: TRIM27; NbExp=3; IntAct=EBI-11953488, EBI-719493;
CC       P56524-2; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-11953488, EBI-744794;
CC       P56524-2; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-11953488, EBI-2799833;
CC       P56524-2; P62258: YWHAE; NbExp=3; IntAct=EBI-11953488, EBI-356498;
CC       P56524-2; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-11953488, EBI-12030590;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Shuttles between the
CC       nucleus and the cytoplasm. Upon muscle cells differentiation, it
CC       accumulates in the nuclei of myotubes, suggesting a positive role of
CC       nuclear HDAC4 in muscle differentiation. The export to cytoplasm
CC       depends on the interaction with a 14-3-3 chaperone protein and is due
CC       to its phosphorylation at Ser-246, Ser-467 and Ser-632 by CaMK4 and
CC       SIK1. The nuclear localization probably depends on sumoylation.
CC       Interaction with SIK3 leads to HDAC4 retention in the cytoplasm (By
CC       similarity). {ECO:0000250|UniProtKB:Q6NZM9}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P56524-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P56524-2; Sequence=VSP_057290, VSP_057291;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: The nuclear export sequence mediates the shuttling between the
CC       nucleus and the cytoplasm.
CC   -!- DOMAIN: The PxLPxI/L motif mediates interaction with ankyrin repeats of
CC       ANKRA2. {ECO:0000269|PubMed:22649097}.
CC   -!- PTM: Phosphorylated by CaMK4 at Ser-246, Ser-467 and Ser-632.
CC       Phosphorylation at other residues by CaMK2D is required for the
CC       interaction with 14-3-3. Phosphorylation at Ser-350, within the
CC       PxLPxI/L motif, impairs the binding of ANKRA2 but generates a high-
CC       affinity docking site for 14-3-3. {ECO:0000269|PubMed:10958686,
CC       ECO:0000269|PubMed:22649097}.
CC   -!- PTM: Sumoylation on Lys-559 is promoted by the E3 SUMO-protein ligase
CC       RANBP2, and prevented by phosphorylation by CaMK4.
CC       {ECO:0000269|PubMed:12032081}.
CC   -!- DISEASE: Note=HDAC4 point mutations and chromosomal microdeletions
CC       encompassing this gene have been found in patients with brachydactyly
CC       and intellectual disability syndrome (PubMed:20691407, PubMed:23188045,
CC       PubMed:24715439). However, HDAC4 haploinsufficiency is not fully
CC       penetrant and multiple genes may contribute to manifestation of the
CC       full phenotypic spectrum (PubMed:23188045, PubMed:24715439).
CC       {ECO:0000269|PubMed:20691407, ECO:0000269|PubMed:23188045,
CC       ECO:0000269|PubMed:24715439}.
CC   -!- DISEASE: Neurodevelopmental disorder with central hypotonia and
CC       dysmorphic facies (NEDCHF) [MIM:619797]: An autosomal dominant disease
CC       characterized by global developmental delay, impaired intellectual
CC       development, seizures, distinctive facial features, scoliosis, delayed
CC       closure of the anterior fontanel, and non-specific brain abnormalities.
CC       {ECO:0000269|PubMed:33537682}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the histone deacetylase family. HD type 2
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA22957.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF132607; AAD29046.1; -; mRNA.
DR   EMBL; AB006626; BAA22957.2; ALT_INIT; mRNA.
DR   EMBL; AC017028; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC062017; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF510800; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF510801; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471063; EAW71165.1; -; Genomic_DNA.
DR   EMBL; BC039904; AAH39904.1; -; mRNA.
DR   CCDS; CCDS2529.1; -. [P56524-1]
DR   RefSeq; NP_001365345.1; NM_001378416.1. [P56524-1]
DR   RefSeq; NP_001365346.1; NM_001378417.1. [P56524-1]
DR   RefSeq; NP_006028.2; NM_006037.4. [P56524-1]
DR   RefSeq; XP_047302435.1; XM_047446479.1. [P56524-1]
DR   RefSeq; XP_054200706.1; XM_054344731.1. [P56524-1]
DR   PDB; 2H8N; X-ray; 2.60 A; A/B/C/D=62-153.
DR   PDB; 2O94; X-ray; 3.00 A; A/B/C/D=62-153.
DR   PDB; 2VQJ; X-ray; 2.10 A; A=648-1057.
DR   PDB; 2VQM; X-ray; 1.80 A; A=648-1057.
DR   PDB; 2VQO; X-ray; 2.15 A; A/B=648-1057.
DR   PDB; 2VQQ; X-ray; 1.90 A; A/B=648-1057.
DR   PDB; 2VQV; X-ray; 3.30 A; A/B=648-1057.
DR   PDB; 2VQW; X-ray; 3.00 A; G=648-1057.
DR   PDB; 3UXG; X-ray; 1.85 A; B=343-359.
DR   PDB; 3UZD; X-ray; 1.86 A; B=343-359.
DR   PDB; 3V31; X-ray; 1.57 A; B=343-359.
DR   PDB; 4CBT; X-ray; 3.03 A; A/B/C=648-1033.
DR   PDB; 4CBY; X-ray; 2.72 A; A/B/C/D=648-1033.
DR   PDB; 5A2S; X-ray; 2.65 A; A/B=648-1033.
DR   PDB; 5ZOO; X-ray; 1.85 A; G=652-1053.
DR   PDB; 5ZOP; X-ray; 2.70 A; G=652-1050.
DR   PDB; 6FYZ; X-ray; 2.15 A; A/B/C=648-1033.
DR   PDB; 7XUZ; X-ray; 3.59 A; A/B=62-192.
DR   PDB; 8PDE; X-ray; 2.40 A; C/X=167-183.
DR   PDBsum; 2H8N; -.
DR   PDBsum; 2O94; -.
DR   PDBsum; 2VQJ; -.
DR   PDBsum; 2VQM; -.
DR   PDBsum; 2VQO; -.
DR   PDBsum; 2VQQ; -.
DR   PDBsum; 2VQV; -.
DR   PDBsum; 2VQW; -.
DR   PDBsum; 3UXG; -.
DR   PDBsum; 3UZD; -.
DR   PDBsum; 3V31; -.
DR   PDBsum; 4CBT; -.
DR   PDBsum; 4CBY; -.
DR   PDBsum; 5A2S; -.
DR   PDBsum; 5ZOO; -.
DR   PDBsum; 5ZOP; -.
DR   PDBsum; 6FYZ; -.
DR   PDBsum; 7XUZ; -.
DR   PDBsum; 8PDE; -.
DR   AlphaFoldDB; P56524; -.
DR   SMR; P56524; -.
DR   BioGRID; 115106; 410.
DR   CORUM; P56524; -.
DR   DIP; DIP-34565N; -.
DR   ELM; P56524; -.
DR   FunCoup; P56524; 3160.
DR   IntAct; P56524; 151.
DR   MINT; P56524; -.
DR   STRING; 9606.ENSP00000264606; -.
DR   BindingDB; P56524; -.
DR   ChEMBL; CHEMBL3524; -.
DR   DrugBank; DB08613; 2,2,2-TRIFLUORO-1-{5-[(3-PHENYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)CARBONYL]THIOPHEN-2-YL}ETHANE-1,1-DIOL.
DR   DrugBank; DB07553; 9,9,9-TRIFLUORO-8-OXO-N-PHENYLNONANAMIDE.
DR   DrugBank; DB12565; Abexinostat.
DR   DrugBank; DB05015; Belinostat.
DR   DrugBank; DB01262; Decitabine.
DR   DrugBank; DB11841; Entinostat.
DR   DrugBank; DB12645; Givinostat.
DR   DrugBank; DB14979; Martinostat.
DR   DrugBank; DB07879; N-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)carbonyl]thiophene-2-carboxamide.
DR   DrugBank; DB06603; Panobinostat.
DR   DrugBank; DB06819; Phenylbutyric acid.
DR   DrugBank; DB03766; Propanoic acid.
DR   DrugBank; DB12847; Pyroxamide.
DR   DrugBank; DB06176; Romidepsin.
DR   DrugBank; DB00313; Valproic acid.
DR   DrugBank; DB02546; Vorinostat.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   DrugCentral; P56524; -.
DR   GuidetoPHARMACOLOGY; 2659; -.
DR   GlyCosmos; P56524; 1 site, 1 glycan.
DR   GlyGen; P56524; 5 sites, 1 O-linked glycan (5 sites).
DR   iPTMnet; P56524; -.
DR   MetOSite; P56524; -.
DR   PhosphoSitePlus; P56524; -.
DR   BioMuta; HDAC4; -.
DR   DMDM; 259016348; -.
DR   jPOST; P56524; -.
DR   MassIVE; P56524; -.
DR   PaxDb; 9606-ENSP00000264606; -.
DR   PeptideAtlas; P56524; -.
DR   ProteomicsDB; 24301; -.
DR   ProteomicsDB; 56920; -. [P56524-1]
DR   ProteomicsDB; 70417; -.
DR   Pumba; P56524; -.
DR   ABCD; P56524; 1 sequenced antibody.
DR   Antibodypedia; 3835; 1232 antibodies from 52 providers.
DR   DNASU; 9759; -.
DR   Ensembl; ENST00000345617.7; ENSP00000264606.3; ENSG00000068024.19. [P56524-1]
DR   GeneID; 9759; -.
DR   KEGG; hsa:9759; -.
DR   UCSC; uc002vyk.4; human. [P56524-1]
DR   AGR; HGNC:14063; -.
DR   ClinPGx; PA29229; -.
DR   CTD; 9759; -.
DR   DisGeNET; 9759; -.
DR   GeneCards; HDAC4; -.
DR   HGNC; HGNC:14063; HDAC4.
DR   HPA; ENSG00000068024; Tissue enhanced (skeletal).
DR   MalaCards; HDAC4; -.
DR   MIM; 605314; gene.
DR   MIM; 619797; phenotype.
DR   OpenTargets; ENSG00000068024; -.
DR   Orphanet; 1001; 2q37 microdeletion syndrome.
DR   VEuPathDB; HostDB:ENSG00000068024; -.
DR   eggNOG; KOG1343; Eukaryota.
DR   GeneTree; ENSGT00940000157440; -.
DR   HOGENOM; CLU_006530_2_0_1; -.
DR   InParanoid; P56524; -.
DR   OrthoDB; 424012at2759; -.
DR   PAN-GO; P56524; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P56524; -.
DR   BRENDA; 3.5.1.98; 2681.
DR   PathwayCommons; P56524; -.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-HSA-4551638; SUMOylation of chromatin organization proteins.
DR   Reactome; R-HSA-8941284; RUNX2 regulates chondrocyte maturation.
DR   Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF.
DR   SignaLink; P56524; -.
DR   SIGNOR; P56524; -.
DR   Agora; ENSG00000068024; -.
DR   BioGRID-ORCS; 9759; 21 hits in 1170 CRISPR screens.
DR   ChiTaRS; HDAC4; human.
DR   EvolutionaryTrace; P56524; -.
DR   GeneWiki; HDAC4; -.
DR   GenomeRNAi; 9759; -.
DR   Pharos; P56524; Tclin.
DR   PRO; PR:P56524; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P56524; protein.
DR   Bgee; ENSG00000068024; Expressed in sural nerve and 199 other cell types or tissues.
DR   ExpressionAtlas; P56524; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IDA:UniProt.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000118; C:histone deacetylase complex; IDA:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcription repressor complex; IDA:BHF-UCL.
DR   GO; GO:0001216; F:DNA-binding transcription activator activity; IDA:BHF-UCL.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0004407; F:histone deacetylase activity; IDA:MGI.
DR   GO; GO:0141221; F:histone deacetylase activity, hydrolytic mechanism; IEA:UniProtKB-EC.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:UniProt.
DR   GO; GO:0030955; F:potassium ion binding; IDA:BHF-UCL.
DR   GO; GO:0033558; F:protein lysine deacetylase activity; IDA:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0019789; F:SUMO transferase activity; EXP:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IDA:BHF-UCL.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; TAS:UniProtKB.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; TAS:BHF-UCL.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:BHF-UCL.
DR   GO; GO:0040029; P:epigenetic regulation of gene expression; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; IDA:BHF-UCL.
DR   GO; GO:0045820; P:negative regulation of glycolytic process; ISS:BHF-UCL.
DR   GO; GO:0010832; P:negative regulation of myotube differentiation; IMP:BHF-UCL.
DR   GO; GO:0061084; P:negative regulation of protein refolding; IDA:UniProtKB.
DR   GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; TAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:BHF-UCL.
DR   GO; GO:0033235; P:positive regulation of protein sumoylation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0016925; P:protein sumoylation; TAS:Reactome.
DR   GO; GO:0014894; P:response to denervation involved in regulation of muscle adaptation; ISS:BHF-UCL.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0060337; P:type I interferon-mediated signaling pathway; IDA:UniProt.
DR   CDD; cd10162; ClassIIa_HDAC4_Gln-rich-N; 1.
DR   CDD; cd10006; HDAC4; 1.
DR   DisProt; DP03448; -.
DR   FunFam; 3.40.800.20:FF:000002; Histone deacetylase; 1.
DR   Gene3D; 6.10.250.1550; -; 1.
DR   Gene3D; 3.40.800.20; Histone deacetylase domain; 1.
DR   IDEAL; IID00457; -.
DR   InterPro; IPR046949; HDAC4/5/7/9.
DR   InterPro; IPR000286; HDACs.
DR   InterPro; IPR023801; His_deacetylse_dom.
DR   InterPro; IPR037138; His_deacetylse_dom_sf.
DR   InterPro; IPR024643; Hist_deacetylase_Gln_rich_N.
DR   InterPro; IPR023696; Ureohydrolase_dom_sf.
DR   PANTHER; PTHR45364:SF13; HISTONE DEACETYLASE; 1.
DR   PANTHER; PTHR45364; HISTONE DEACETYLASE 9-RELATED; 1.
DR   Pfam; PF12203; HDAC4_Gln; 1.
DR   Pfam; PF00850; Hist_deacetyl; 1.
DR   PIRSF; PIRSF037911; HDAC_II_euk; 1.
DR   PRINTS; PR01270; HDASUPER.
DR   SUPFAM; SSF52768; Arginase/deacetylase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromatin regulator; Coiled coil;
KW   Cytoplasm; Disease variant; Epilepsy; Hydrolase; Intellectual disability;
KW   Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc.
FT   CHAIN           1..1084
FT                   /note="Histone deacetylase 4"
FT                   /id="PRO_0000114699"
FT   REGION          118..313
FT                   /note="Interaction with MEF2A"
FT                   /evidence="ECO:0000269|PubMed:10487761"
FT   REGION          133..166
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          206..226
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          240..315
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          509..531
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          548..585
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          626..646
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          655..1084
FT                   /note="Histone deacetylase"
FT   REGION          1061..1084
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          67..177
FT                   /evidence="ECO:0000255"
FT   MOTIF           349..354
FT                   /note="PxLPxI/L motif; mediates interaction with ANKRA2 and
FT                   14-3-3 proteins"
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MOTIF           1051..1084
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        133..163
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        259..274
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        290..312
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        516..531
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        629..641
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        803
FT                   /evidence="ECO:0000250"
FT   BINDING         667
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         669
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         675
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         751
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         210
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6NZM9"
FT   MOD_RES         246
FT                   /note="Phosphoserine; by CaMK4 and SIK1"
FT                   /evidence="ECO:0000269|PubMed:10958686"
FT   MOD_RES         350
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22649097,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         467
FT                   /note="Phosphoserine; by CaMK4 and SIK1"
FT                   /evidence="ECO:0000269|PubMed:10958686"
FT   MOD_RES         565
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6NZM9"
FT   MOD_RES         632
FT                   /note="Phosphoserine; by CaMK4"
FT                   /evidence="ECO:0000269|PubMed:10958686,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         633
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   CROSSLNK        559
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:12032081"
FT   VAR_SEQ         1..117
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_057290"
FT   VAR_SEQ         431
FT                   /note="T -> TDWYLS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_057291"
FT   VARIANT         244
FT                   /note="T -> K (in NEDCHF; decreased interaction with YWHAB;
FT                   dbSNP:rs2042442594)"
FT                   /evidence="ECO:0000269|PubMed:33537682"
FT                   /id="VAR_087034"
FT   VARIANT         247
FT                   /note="E -> G (in NEDCHF; decreased interaction with YWHAB;
FT                   dbSNP:rs2152917896)"
FT                   /evidence="ECO:0000269|PubMed:33537682"
FT                   /id="VAR_087035"
FT   VARIANT         248
FT                   /note="P -> A (in NEDCHF; dbSNP:rs2152917882)"
FT                   /evidence="ECO:0000269|PubMed:33537682"
FT                   /id="VAR_087036"
FT   VARIANT         248
FT                   /note="P -> L (in NEDCHF; dbSNP:rs1064797002)"
FT                   /evidence="ECO:0000269|PubMed:33537682"
FT                   /id="VAR_087037"
FT   VARIANT         727
FT                   /note="P -> R (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036042"
FT   VARIANT         754
FT                   /note="V -> I (in dbSNP:rs151043798)"
FT                   /evidence="ECO:0000269|PubMed:24169519"
FT                   /id="VAR_071965"
FT   MUTAGEN         246
FT                   /note="S->A: Reduces phosphorylation and its subsequent
FT                   nuclear export."
FT                   /evidence="ECO:0000269|PubMed:10958686"
FT   MUTAGEN         345
FT                   /note="L->A: No effect on interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         346
FT                   /note="Y->A: No effect on interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         347
FT                   /note="T->A: No effect on interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         348
FT                   /note="S->A: No effect on interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         349
FT                   /note="P->A: May affect interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097,
FT                   ECO:0000269|PubMed:25752541"
FT   MUTAGEN         349
FT                   /note="P->G: Decreased interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         350
FT                   /note="S->A: No effect on interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         351
FT                   /note="L->A,G: Loss of interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         352
FT                   /note="P->A: Loss of interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         353
FT                   /note="N->A: No effect on interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         354
FT                   /note="I->A: May affect interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097,
FT                   ECO:0000269|PubMed:25752541"
FT   MUTAGEN         354
FT                   /note="I->G: Loss of interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         355
FT                   /note="T->A: No effect on interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         356
FT                   /note="L->A: No effect on interaction with ANKRA2."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         467
FT                   /note="S->A: Reduces phosphorylation and its subsequent
FT                   nuclear export."
FT                   /evidence="ECO:0000269|PubMed:10958686,
FT                   ECO:0000269|PubMed:11470791"
FT   MUTAGEN         559
FT                   /note="K->R: Abolishes sumoylation and reduces the histone
FT                   deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:12032081"
FT   MUTAGEN         632
FT                   /note="S->A: Reduces phosphorylation and its subsequent
FT                   nuclear export."
FT                   /evidence="ECO:0000269|PubMed:10958686,
FT                   ECO:0000269|PubMed:11470791"
FT   MUTAGEN         803
FT                   /note="H->L: Abolishes histone deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:10523670"
FT   MUTAGEN         1056
FT                   /note="V->A: Reduces CaMK-dependent nuclear export."
FT                   /evidence="ECO:0000269|PubMed:11509672"
FT   MUTAGEN         1062
FT                   /note="L->A: Reduces CaMK-dependent nuclear export."
FT                   /evidence="ECO:0000269|PubMed:11509672"
FT   CONFLICT        373
FT                   /note="A -> T (in Ref. 1; AAD29046 and 2; BAA22957)"
FT                   /evidence="ECO:0000305"
FT   HELIX           64..112
FT                   /evidence="ECO:0007829|PDB:2H8N"
FT   HELIX           115..121
FT                   /evidence="ECO:0007829|PDB:2H8N"
FT   TURN            122..125
FT                   /evidence="ECO:0007829|PDB:2H8N"
FT   HELIX           126..128
FT                   /evidence="ECO:0007829|PDB:2H8N"
FT   TURN            354..357
FT                   /evidence="ECO:0007829|PDB:3UXG"
FT   STRAND          652..657
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           660..662
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           672..674
FT                   /evidence="ECO:0007829|PDB:5ZOO"
FT   HELIX           681..691
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           694..697
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          698..701
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           708..711
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   TURN            712..714
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           717..724
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           727..730
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           737..745
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          746..748
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          754..756
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           762..786
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          789..795
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          813..815
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           817..828
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          834..838
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          840..842
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           845..851
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          857..864
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           866..868
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          870..872
FT                   /evidence="ECO:0007829|PDB:6FYZ"
FT   HELIX           883..885
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          889..894
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          898..900
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           904..913
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           915..922
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          925..931
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          936..938
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   TURN            940..943
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           950..961
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           964..966
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   STRAND          968..972
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           978..992
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           1002..1006
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           1011..1025
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           1029..1031
FT                   /evidence="ECO:0007829|PDB:2VQM"
FT   HELIX           1042..1047
FT                   /evidence="ECO:0007829|PDB:2VQM"
SQ   SEQUENCE   1084 AA;  119040 MW;  BB7FD37652D12398 CRC64;
     MSSQSHPDGL SGRDQPVELL NPARVNHMPS TVDVATALPL QVAPSAVPMD LRLDHQFSLP
     VAEPALREQQ LQQELLALKQ KQQIQRQILI AEFQRQHEQL SRQHEAQLHE HIKQQQEMLA
     MKHQQELLEH QRKLERHRQE QELEKQHREQ KLQQLKNKEK GKESAVASTE VKMKLQEFVL
     NKKKALAHRN LNHCISSDPR YWYGKTQHSS LDQSSPPQSG VSTSYNHPVL GMYDAKDDFP
     LRKTASEPNL KLRSRLKQKV AERRSSPLLR RKDGPVVTAL KKRPLDVTDS ACSSAPGSGP
     SSPNNSSGSV SAENGIAPAV PSIPAETSLA HRLVAREGSA APLPLYTSPS LPNITLGLPA
     TGPSAGTAGQ QDAERLTLPA LQQRLSLFPG THLTPYLSTS PLERDGGAAH SPLLQHMVLL
     EQPPAQAPLV TGLGALPLHA QSLVGADRVS PSIHKLRQHR PLGRTQSAPL PQNAQALQHL
     VIQQQHQQFL EKHKQQFQQQ QLQMNKIIPK PSEPARQPES HPEETEEELR EHQALLDEPY
     LDRLPGQKEA HAQAGVQVKQ EPIESDEEEA EPPREVEPGQ RQPSEQELLF RQQALLLEQQ
     RIHQLRNYQA SMEAAGIPVS FGGHRPLSRA QSSPASATFP VSVQEPPTKP RFTTGLVYDT
     LMLKHQCTCG SSSSHPEHAG RIQSIWSRLQ ETGLRGKCEC IRGRKATLEE LQTVHSEAHT
     LLYGTNPLNR QKLDSKKLLG SLASVFVRLP CGGVGVDSDT IWNEVHSAGA ARLAVGCVVE
     LVFKVATGEL KNGFAVVRPP GHHAEESTPM GFCYFNSVAV AAKLLQQRLS VSKILIVDWD
     VHHGNGTQQA FYSDPSVLYM SLHRYDDGNF FPGSGAPDEV GTGPGVGFNV NMAFTGGLDP
     PMGDAEYLAA FRTVVMPIAS EFAPDVVLVS SGFDAVEGHP TPLGGYNLSA RCFGYLTKQL
     MGLAGGRIVL ALEGGHDLTA ICDASEACVS ALLGNELDPL PEKVLQQRPN ANAVRSMEKV
     MEIHSKYWRC LQRTTSTAGR SLIEAQTCEN EEAETVTAMA SLSVGVKPAE KRPDEEPMEE
     EPPL
//
